Innovating Works

BiotechSubsidy

Desconocido
TIGER: Proof of Principle of the best in class therapeutic mRNA cancer vaccine PATERGRUS BVBA participó en un H2020: H2020-SC1-BHC-2018-2020 TIGER delivers proof of principle (PoP) in humans for a novel best-in-class therapeutic mRNA cancer vaccine platform optimized for intraveno...
2021-02-15 - 2025-07-31 | Financiado
HIT-CF: Personalised Treatment For Cystic Fibrosis Patients With Ultra rare CFTR Mutations and beyond PATERGRUS BVBA participó en un H2020: H2020-SC1-2016-2017 In our HIT-CF project, we aim to bring personalised disease modifying therapies to cystic fibrosis (CF) patients with ultra-rare CFTR mutati...
2017-11-28 - 2025-06-30 | Financiado
SUPERBIO: SUpport and PartnERship for the development of multiple sustainable and market ready value chains in... PATERGRUS BVBA participó en un H2020: H2020-INNOSUP-2014-2015 SUPERBIO focuses on the biobased economy. This emerging economy relies on the use of biomass (e.g. plants, waste) as renewable raw material...
2016-06-20 - 2019-03-31 | Financiado
PRO-CF-MED: Clinical Proof of concept for a RNA targeting Oligonucleotide for a Cystic fibrosis F508del MEDicati... PATERGRUS BVBA participó en un H2020: H2020-PHC-2014-2015 Cystic fibrosis (CF) is a progressive life-shortening disease caused by a mutation in the cystic fibrosis transmembrane conductance regulato...
2015-04-21 - 2017-12-31 | Financiado
FIGHT-HLH: First Targeted Therapy to FIGHT Hemophagocytic Lymphohistiocytosis HLH A novel approach to HLH PATERGRUS BVBA participó en un FP7: Hemophagocytic lymphohistiocytosis (HLH) is a rare, devastating disease characterized by uncontrolled immune response that primarily affects...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.